Market Place
Sourcing Support
Immutep Reports Phase I LAG-3 Progress in Autoimmune Diseases
19 Mar 2026 //
GLOBENEWSWIRE
Immutep`s Ph. 3 Failure Surprises Analysts, Sinks Stock
14 Mar 2026 //
FIERCE BIOTECH
Immutep Reaches 50% Enrollment In Global Phase III Trial For 1L
06 Feb 2026 //
GLOBENEWSWIRE
Immutep Reports Strong Progress in TACTI-004 Phase III Trial
16 Dec 2025 //
GLOBENEWSWIRE
Immutep Presents New AIPAC-003 Phase II Data at 2025 SABCS
02 Dec 2025 //
GLOBENEWSWIRE
EFTISARC-NEO Ph II Data Highlighted In CTOS 2025 Presentation
13 Nov 2025 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q1 FY26
29 Oct 2025 //
GLOBENEWSWIRE
EFTISARC-NEO Ph2 Meets Endpoint for Efti in Soft Tissue Sarcoma
20 Oct 2025 //
GLOBENEWSWIRE
Immutep Showcases Treatment Innovation In First-Line Lung Cancer
20 Oct 2025 //
GLOBENEWSWIRE
Immutep Completes FDA Project Optimus Requirements
13 Oct 2025 //
GLOBENEWSWIRE
Immutep Shares Update on Ph3 TACTI-004 Trial in Lung Cancer
09 Oct 2025 //
GLOBENEWSWIRE
Immutep Collaborates With Gw Cancer Center To Evaluate
22 Sep 2025 //
GLOBENEWSWIRE
Immutep to Present Ph2 EFTISARC-NEO Efti Data in Sarcoma at CTOS
08 Sep 2025 //
GLOBENEWSWIRE
Immutep Gets FDA Feedback on Efti in HNC With CPS Under 1
05 Aug 2025 //
GLOBENEWSWIRE
Immutep Q4 FY25 Activities Report
30 Jul 2025 //
GLOBENEWSWIRE
Immutep to Showcase TACTI-004 Trial Poster at Lung Cancer Conf
29 Jul 2025 //
GLOBENEWSWIRE
Immutep Abstracts Accepted for 2025 ESMO Congress
28 Jul 2025 //
GLOBENEWSWIRE
Immutep reports positive Phase I results for LAG-3 antibody
23 Jun 2025 //
GLOBENEWSWIRE
Immutep Combo Hits Endpoint in Ph2 Sarcoma Study
27 May 2025 //
GLOBENEWSWIRE
Immutep’s efti with PD-L1 achieves high response in lung cancer
16 May 2025 //
GLOBENEWSWIRE
Immutep to Participate in Upcoming Investor Conferences
02 Apr 2025 //
GLOBENEWSWIRE
Immutep to Present TACTI-004 Trial Poster at Lung Cancer Congress
20 Mar 2025 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q2 FY25
31 Jan 2025 //
GLOBENEWSWIRE
Immutep Reports Initial Safety Data from IMP761 Phase I Trial
17 Dec 2024 //
GLOBENEWSWIRE
Immutep Reports New Data in Head & Neck Cancer at ESMO 2024
12 Dec 2024 //
GLOBENEWSWIRE
Immutep Initiates TACTI-004 Phase III Trial in 1st Line NSCLC
10 Dec 2024 //
GLOBENEWSWIRE
Positive Phase II Data in Soft Tissue Sarcoma Presented at CTOS
14 Nov 2024 //
GLOBENEWSWIRE
Immutep’s Efti Shows Survival Data from INSIGHT-003 in NSCLC
14 Nov 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q1 FY25
29 Oct 2024 //
GLOBENEWSWIRE
Immutep Presents Phase IIb Data in Head and Neck Cancer at ESMO
28 Oct 2024 //
#N/A
Immutep Advances First-in-Human Study Of IMP761 To Dose Escalation
17 Oct 2024 //
GLOBENEWSWIRE
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
10 Oct 2024 //
GLOBENEWSWIRE
Immutep Completes AIPAC-003 Trial Enrollment For Breast Cancer
03 Oct 2024 //
GLOBENEWSWIRE
Immutep Receives A$3.6 million R&D Tax Incentive from Government
24 Sep 2024 //
GLOBENEWSWIRE
New Efti Combination Data To Be Presented For Sarcoma
18 Sep 2024 //
GLOBENEWSWIRE
Immutep`s Efti Shows Positive Results In Head And Neck Cancer
16 Sep 2024 //
GLOBENEWSWIRE
Immutep Doses First Participant In Phase I Study Of IMP761 LAG-3 Antibody
14 Aug 2024 //
GLOBENEWSWIRE
Immutep, Merck Collaborate On Efti Plus KEYTRUDA In Pivotal Phase III
02 Jun 2024 //
GLOBENEWSWIRE
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA
09 Nov 2023 //
GLOBENEWSWIRE
Immutep Announces New Biomarker Data from TACTI-002 Phase II
03 Nov 2023 //
GLOBENEWSWIRE
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
30 May 2023 //
GLOBENEWSWIRE
Immutep Efti in Combination with Pembrolizumab Achieves Benefit in 1L NSCLC
17 May 2023 //
GLOBENEWSWIRE
Immutep Announces KOL Event Focused on Eftilagimod Alpha
02 May 2023 //
GLOBENEWSWIRE
Immutep Receives Approval to Initiate INSIGHT-005 Trial Eftilagimod Alpha
01 May 2023 //
GLOBENEWSWIRE
